Tirzepatide vs Wegovy: Key Clinical Differences

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Tirzepatide and Wegovy are fundamentally different medications with distinct mechanisms of action, despite both being prescribed for weight management. Tirzepatide is a dual GLP-1/GIP receptor agonist, while Wegovy contains semaglutide, a GLP-1-only agonist. This distinction affects dosing, efficacy profiles, and how individual patients may respond.

For patients exploring treatment options, understanding these differences—alongside individual metabolic factors and genetic predispositions—supports more informed conversations with healthcare providers. Precision-wellness approaches increasingly recognize that medication selection and response vary significantly between individuals, making personalized evaluation essential before starting any medication.

Mechanism of Action: Dual Receptor versus Single Receptor

Tirzepatide activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Wegovy activates the GLP-1 receptor only. This dual-receptor mechanism in tirzepatide may enhance insulin secretion and glucose control through a different biological pathway than semaglutide-based formulations.

Clinical trials suggest tirzepatide may produce greater weight loss and metabolic improvements in some patients, though individual response varies considerably. Both medication classes work by slowing gastric emptying, reducing appetite signaling, and improving insulin sensitivity—but the dual action of tirzepatide engages additional metabolic pathways.

Clinical Efficacy, Dosing, and Individual Response Patterns

Comparative data from randomized trials provides context for understanding expected outcomes, though real-world results depend on individual baseline metabolism, adherence, and lifestyle factors. Neither medication guarantees identical weight loss or metabolic improvements across all patients. Dosing schedules, dose escalation timing, and maximum tolerated doses also differ between tirzepatide and semaglutide formulations.

Factor	Tirzepatide	Wegovy (Semaglutide)
Receptor Target	Dual: GLP-1 + GIP	Single: GLP-1 only
Typical Starting Dose	2.5 mg weekly	0.25 mg weekly
Maximum Approved Dose	15 mg weekly	2.4 mg weekly
Median Weight Loss (Trial Data)	Up to 22% in SUMO trials	Up to 15% in STEP trials
Dosing Schedule	Weekly subcutaneous injection	Weekly subcutaneous injection
Expected Dose Escalation Period	8-12 weeks to maintenance	16-20 weeks to 2.4 mg
Common Side Effects	Nausea, vomiting, GI upset	Nausea, vomiting, GI upset
Individual Response Variability	High—genetic and biomarker factors influence response	High—baseline metabolic status affects outcomes

Cost, Access, and Compounded versus Branded Options

Branded Wegovy and Mounjaro (tirzepatide) typically cost $900–$1,300 monthly without insurance coverage, though some patients qualify for manufacturer assistance programs. Compounded tirzepatide and semaglutide—prepared by licensed 503A compounding pharmacies—offer transparent pricing and may be more accessible, though compounded formulations are not FDA-approved and differ from branded products in manufacturing oversight.

PlexusDx offers compounded tirzepatide injection ($249/mo) and compounded semaglutide injection ($149/mo) through licensed 503A pharmacies, providing patients with cost-transparent alternatives. Choosing between compounded and branded options requires discussion with a healthcare provider regarding regulatory status, supply reliability, and individual medical history.

Who Benefits Most and Important Safety Considerations

Both tirzepatide and semaglutide are contraindicated in patients with personal or family history of medullary thyroid carcinoma, and require careful evaluation in those with type 2 diabetes, pancreatitis history, or severe GI conditions. Pregnant or nursing patients should avoid both medications. Individual medical history, current medications, and metabolic status must be evaluated by a qualified healthcare provider before initiation.

Patients with elevated baseline A1C, significant insulin resistance, or inadequate response to GLP-1-only medications may warrant exploration of tirzepatide's dual-receptor mechanism with their provider. Conversely, patients with mild glucose dysregulation or simpler metabolic profiles may achieve desired outcomes with semaglutide. Genetic predispositions in peptide pathway genes (GLP1R, GIPR, MC4R, FTO) may provide context for individual response variability.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP1R, GIPR, MC4R, and FTO genes that influence how individuals metabolize and respond to peptide-based medications. These genetic predispositions may help provide context for expected medication response patterns and can support more informed discussions with your healthcare provider about whether tirzepatide's dual-receptor mechanism or semaglutide's single-receptor approach aligns better with your genetic profile.

The genetic test reveals predispositions in peptide pathways—not exact medication response. A patient with certain GLP1R or GIPR variants may demonstrate different baseline insulin sensitivity or appetite regulation, which could theoretically influence tirzepatide versus semaglutide efficacy. However, genetic predisposition is one factor among many; lifestyle, baseline metabolic status, and adherence remain critical determinants of real-world outcomes.

Combining genetic insights with clinical evaluation—baseline weight, metabolic markers (glucose, insulin, lipids), and medical history—creates a more complete picture for personalizing treatment selection. Whether you choose compounded tirzepatide, compounded semaglutide, or branded alternatives, discussing genetic context alongside clinical biomarkers with your provider can help refine the decision-making process and set realistic expectations for treatment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.